Psychedelics Beyond Serotonin: Ibogaine & Ketamine
September 26 @ 6:30 pm - 9:00 pm
While most psychedelics produce their effects by modulating serotonin, there are exceptions of worthy mention including ibogaine and ketamine. While vastly different in their effects, both ibogaine and ketamine appear to modulate either glutamate or opioid systems. Ibogaine is often touted for its powerful anti-addictive properties, although it carries risks of cardiotoxicity. Ketamine has built a strong evidence base in the treatment of depression, amongst other refractory conditions. The fourth installment will take a closer look at each of these ‘novel’ psychedelics.
This is the fourth of a 5-part workshop series geared toward providing a foundation for understanding the psychopharmacology and clinical research of the most commonly encountered psychedelic compounds as well as practical information for safe psychedelic use. Seating is limited so sign up today!
Benjamin Malcolm teaches psychopharmacology, practices as a clinical psychiatric specialist, and performs research on psychoactive drugs including psychedelics. His educational background consists of a bachelor’s degree in pharmacology, a doctorate of pharmacy, a master’s degree in public health and specialized post-doctoral training in psychiatry. He’s a lover of nature, exercise, music and consciousness as well as being a husband and father. He’s passionate about psychedelic drugs and envisions a society in which they are available in safe and supported settings for psychospiritual well-being, personal growth, ceremonial sacrament, and treatment of mental illness. Additionally, he runs a psychopharmacology consulting service on his website, spiritpharmacist.com, to help those in need for an informational risk evaluation of psychedelic use.